Hypertension Diagnostics, Inc. (HDII) Stock

About Hypertension Diagnostics, Inc.

Hypertension Diagnostics, Inc. (HDII) is a company that designs, develops, manufactures, and commercializes its own innovative, non-invasive medical technologies. These devices are engineered to identify minute changes in the flexibility of arteries, serving both domestic and international markets. Central to their offerings is the CVProfilor, a system designed for non-invasive assessment of both large and small artery elasticity. The elasticity of small arteries is especially critical, serving as the earliest and most sensitive indicator of cardiovascular disease. The product suite includes the CVProfilor DO-2020, which delivers essential arterial elasticity indices, aiding in the diagnosis of underlying vascular conditions. Its counterpart, the CVProfilor MD-3000, offers precise and specific insights into the presence of blood vessel disease. For scientific study, the HD/PulseWave CR-2000 is a specialized cardiovascular profiling system, equipping scientists and investigators with a non-intrusive method to evaluate arterial elasticity across diverse human research domains. These devices operate by capturing 30 seconds of blood pressure waveform data, subsequently analyzing the digitized patterns to generate a comprehensive CVProfile report. This report details crucial metrics including blood pressure, heart rate, pulse pressure, body surface area, body mass index, and indices for both C1 (large) and C2 (small) artery elasticity. HDII caters to a broad spectrum of clients, including general practitioners, cardiologists, various healthcare practitioners, skilled medical staff, academic and government research scientists, cardiovascular specialists, and pharmaceutical companies. In the U.S., sales are facilitated by a dedicated network of representatives. Established in 1988, Hypertension Diagnostics, Inc. maintains its headquarters in Richmond Hill, Canada.

Hypertension Diagnostics, Inc. (HDII) stock trades at $0.00 with a market capitalization of $13681. The stock is valued at a price-to-earnings (P/E) ratio of -0.25, price-to-book of -0.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Hypertension Diagnostics, Inc. generates a return on equity (ROE) of 18.01%, above the typical market average, return on capital employed of 100.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.hypertensiondiagnostics.com